Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Trial, condition or NCT IDCountrySponsorPhaseStatusConditionReset

9 trials match this view; 10 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 1,141 across 9 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Export filtered registry facts · JSONInteractive world map Germany source-checked report

Recorded study-start years

200911

201411

201511

202311

202511

202644

Current indexed registry status

Recruiting44

Completed33

Not yet recruiting22

Reported research conditions

Anhedonia11

Emotional Blunting11

Alcohol Use Disorder11

IBS - Irritable Bowel Syndrome11

Opioid Use Disorder11

Stuttering11

Advanced Cancer11

Alcohol Dependence11

Religious or Spiritual Problem11

Cancer11

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

9 matching registry records. Dates are registry milestones, not promised results announcements.
Trial	Sponsor and phase	Status	Enrollment	Start / primary completion / completion
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia NCT07607938 Anhedonia · Emotional Blunting	NYU Langone Health PHASE1	Recruiting Registry updated 2026-09-15	90 ESTIMATED	2026-09 2030-08-01 2030-09-30
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder NCT06349083 Alcohol Use Disorder	NYU Langone Health PHASE2	Recruiting Registry updated 2026-09-02	200 ESTIMATED	2026-09-01 2030-05 2030-05
Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome. NCT06760533 IBS - Irritable Bowel Syndrome	NYU Langone Health EARLY_PHASE1	Not yet recruiting Registry updated 2026-03-05	10 ESTIMATED	2026-08 2026-12 2026-12
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment NCT06796062 Opioid Use Disorder	NYU Langone Health PHASE2	Recruiting Registry updated 2026-01-23	480 ESTIMATED	2025-12-17 2029-02 2029-02
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter NCT07296328 Stuttering	NYU Langone Health PHASE2	Not yet recruiting Registry updated 2025-12-22	25 ESTIMATED	2026-01-15 2027-04-01 2027-04-01
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer NCT05398484 Advanced Cancer	NYU Langone Health PHASE2, PHASE3	Recruiting Registry updated 2025-12-04	200 ESTIMATED	2023-05-24 2027-01-01 2027-01-01
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence NCT02061293 Alcohol Dependence	NYU Langone Health PHASE2	Completed Registry updated 2022-11-08	95 ACTUAL	2014-06 2021-07-30 2021-07-30
A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion NCT02421263 Religious or Spiritual Problem	NYU Langone Health PHASE1	Completed Registry updated 2022-02-14	12 ACTUAL	2015-04 2020-06-05 2020-06-05
Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients NCT00957359 Cancer	NYU Langone Health EARLY_PHASE1	Completed Registry updated 2020-10-20	29 ACTUAL	2009-02 2018-09-06 2018-09-06

Reported research facilities

NYU Langone HealthNew York, New York, United States

Duke City Recovery ToolboxAlbuquerque, New Mexico, United States

University of New MexicoAlbuquerque, New Mexico, United States

StartCareBrooklyn, New York, United States

VIP Community Services, IncThe Bronx, New York, United States

University of Colorado Anschutz Medical campus (CU AMC)Aurora, Colorado, United States

University of New Mexico Health Sciences CenterAlbuquerque, New Mexico, United States

Clinical and Translational Science Institute, NYU Langone Medical CenterNew York, New York, United States

NYU Langone Medical Center/Tisch HospitalNew York, New York, United States

NYU College of Dentistry Bluestone Center for Clinical ResearchNew York, New York, United States

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.